Income StatementBalance SheetCash FlowSegments
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Vertex Pharmaceuticals holds $26.5B in total assets. Shareholders' equity is $19.4B against $2.0B in total debt. Cash and equivalents total $5.5B. The current ratio is 3.02 and debt-to-equity is 0.103. Based on the Q1 2026 filing.

Total Assets$26.5BTotal Stockholders Equity$19.4BCash And Equivalents$5.5BTotal Current Assets$11.7BTotal Current Liabilities$3.9B
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$110.28B
P/E Ratio25.42
ROE24.2%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$413.0M$445.0M$442.3M$420.3M$461.7M$489.3M
Other Commercial Liabilities$2.8B$3.0B$3.3B$3.6B$3.0B$3.0B
Accrued Liabilities, Current$2.8B$3.0B$3.3B$3.6B$3.0B$3.0B
Other accrued liabilities$363.0M$386.4M$425.4M$441.5M$428.3M$407.1M
Total current liabilities$3.6B$3.8B$4.1B$4.5B$3.9B$3.9B

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$1.6B$1.8B$1.9B$1.9B$2.1B$2.0B
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)—$100.0K$100.0K$100.0K—$100.0K
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value—$100.0K$100.0K$100.0K—$100.0K
AFS and Trading Securities - Unrealized Loss Position Fair Value—$1.1B$816.0M$463.1M—$3.4B
Cash and cash equivalents$4.6B$4.7B$5.0B$4.9B$5.1B$5.5B
Finished goods$184.6M$208.0M$214.3M$252.0M$230.1M$255.9M
Short- term Investments$1.5B$1.5B$1.4B$1.3B$1.5B$1.8B
Current Equity Amortized Cost$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Equity Securities (FV-NI) - Cost Basis$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Raw materials$252.0M$250.5M$221.4M$278.6M$259.8M$267.4M
Work in process$768.8M$901.2M$1.1B$1.1B$1.2B$1.2B
Inventories$1.2B$1.4B$1.5B$1.6B$1.7B$1.8B
Prepaid expenses and other current assets$665.7M$642.8M$652.3M$709.4M$853.3M$720.8M
Restricted cash$2.6M$10.7M$9.8M$8.2M$3.0M$12.0M
Short-term investments$1.5B$1.5B$1.4B$1.3B$1.5B$1.8B
Total current assets$9.6B$10.0B$10.4B$10.6B$11.2B$11.7B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss—$7.6M$6.2M$9.9M—$8.4M
Accumulated other comprehensive income (loss)$127.8M$68.1M-$101.1M-$64.5M-$15.9M$24.8M
Additional paid-in capital$6.7B$6.2B$6.0B$5.0B$5.1B$4.7B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$2.6M$2.6M$2.6M$2.5M$2.5M$2.5M
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0.0$0.0$0.0$0.0$0.0$0.0
Investments - Gross Unrealized Losses—$1.1B$816.0M$463.1M—$3.4B
Retained earnings$9.6B$10.3B$11.3B$12.4B$13.6B$14.6B
Share Repurchase Program - Amount Remaining—$964.4M$4.6B$3.5B—$3.0B
Total liabilities and stockholders' equity$22.5B$22.9B$24.0B$24.9B$25.6B$26.5B
Total stockholders' equity$16.4B$16.5B$17.2B$17.3B$18.7B$19.4B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Cumulative Cost Basis$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax—$2.2M$1.2M$800.0K—$13.2M
Business Combination, Contingent Consideration, Liability$76.9M$79.1M$80.0M$78.1M$79.0M$79.2M
Fair Value$1.7B$1.4B$1.0B$1.2B$2.8B$2.6B
Cash Equivalents And Debt Securities, Available for Sale$1.7B$1.4B$1.0B$1.2B$2.8B$2.6B
Cash Equivalents, Debt and Equity Securities, Cost$8.4B$8.1B$8.1B$8.3B$10.0B$10.1B
Total cash equivalents and marketable securities, Fair Value$8.3B$8.1B$8.1B$8.3B$10.0B$10.1B
Total cash equivalents and marketable securities, Gross Unrealized Gains$22.8M$32.5M$41.0M$45.1M$44.3M$16.9M
Cash Equivalents, Debt and Equity Securities, Unrealized Loss$49.1M$40.6M$33.3M$16.4M$9.0M$17.8M
Common stock, par value (in dollars per share)$0.01$0.01$0.01$0.01$0.01$0.01
Common stock, shares authorized (in shares)500M500M500M500M500M500M
Common stock, shares issued (in shares)256.9M257M256.3M254M254M254.2M
Common Stock, Shares, Outstanding256.9M257M256.3M254M254M254.2M
Contingent liabilities$0.0$0.0$0.0$0.0$0.0$0.0
Contract with Customer, Liability$206.8M$228.4M$146.9M$182.0M$171.8M$218.7M
Debt Securities, Available-for-Sale, Allowance for Credit Loss—$0.0$0.0$0.0—$0.0
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss—$7.6M$6.2M$9.9M—$8.4M
12 months or more—$100.0K$100.0K$100.0K—$100.0K
Debt Securities, Available-for-Sale, Unrealized Loss Position—$1.1B$816.0M$463.1M—$3.4B
Debt and Equity Securities, Cost$6.7B$6.7B$7.0B$7.0B$7.2B$7.5B
Fair Value$6.7B$6.7B$7.1B$7.1B$7.2B$7.5B
Gross 
Unrealized 
Gains$22.8M$32.5M$41.0M$45.1M$44.3M$16.9M
Debt and Equity Securities, Unrealized Loss$49.1M$40.6M$33.3M$16.4M$9.0M$17.8M
Cost$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Finite-Lived Intangible Assets, Accumulated Amortization$23.4M$29.1M$34.8M$40.5M$46.1M$51.8M
Indemnification claims—$0.0$0.0$0.0—$0.0
Indefinite- lived intangible impairment$849.3M$470.3M$470.3M$470.3M$470.3M$470.3M
Loss Contingency Accrual$0.0—$0.0$0.0$0.0$0.0
Preferred Stock, Par or Stated Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Preferred Stock, Shares Authorized1M1M1M1M1M1M
Preferred Stock, Shares Issued000000
Share Repurchase Program, Remaining Authorized, Amount—$964.4M$4.6B$3.5B—$3.0B
Amount that if recognized, would affect the effective tax rate or regulatory liability$341.4M$357.4M$412.1M$421.6M$436.6M$420.3M

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Deferred Tax Assets and Other Non-Current Assets$999.3M$1.0B$1.1B$1.1B$1.2B$1.3B
Equity Amortized Cost$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Goodwill$1.1B$1.1B$1.1B$1.1B$1.1B$1.1B
Equity securities$36.6M$21.6M$27.9M$9.4M$16.6M$20.4M
Investments - Cost Basis$72.1M$60.0M$60.0M$25.0M$25.0M$25.0M
Net Investment in Lease$1.4B$1.3B$1.3B$1.6B$1.6B$1.7B
Deferred tax assets$2.3B$2.5B$2.7B$2.9B$2.9B$2.9B
Other intangible assets—net$825.9M$441.2M$435.5M$429.8M$424.2M$418.5M
Long- term Investments$5.1B$5.2B$5.6B$5.7B$5.7B$5.7B
Operating lease right-of-use assets$1.4B$1.3B$1.3B$1.6B$1.6B$1.7B
Other non-current assets$999.3M$1.0B$1.1B$1.1B$1.2B$1.3B
Property, plant and equipment, net$1.2B$1.3B$1.3B$1.4B$1.5B$1.6B
Operating Lease Right-of-Use Assets in Other Assets$1.4B$1.3B$1.3B$1.6B$1.6B$1.7B
Software and Technology Licenses, Net$999.3M$1.0B$1.1B$1.1B$1.2B$1.3B
Total assets$22.5B$22.9B$24.0B$24.9B$25.6B$26.5B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating lease liabilities, non-current$1.5B$1.5B$1.5B$1.8B$1.8B$2.0B
Other non-current liabilities$1.0B$951.9M$1.2B$1.2B$1.3B$1.3B
Total liabilities$6.1B$6.4B$6.9B$7.5B$7.0B$7.1B